Table 3.
Results of patient-reported outcomes—PFDI-SF20, PFIQ-7 and PISQ-12
| Outcome measure Timepoint |
Oestrogen N; mean (SD) |
No treatment N; mean (SD) |
Mean difference between groups (95% CI)‡ |
| PFDI-SF20; POPDI-6 domain (0–100, higher=worse pain)* | |||
| Baseline | n=48; | n=49; | |
| 43.4 (24.8) | 46.0 (24.4) | ||
| 6 months | n=38; | n=41; | 4.1 (−3.9 to 12.1) |
| 16.3 (20.3) | 12.5 (11.6) | ||
| 12 months | n=37; | n=41; | 4.4 (−4.7 to 13.5) |
| 16.7 (20.6) | 14.6 (15.6) | ||
| PFDI-SF20; CRADI-8 domain (0–100, higher=worse pain)* | |||
| Baseline | n=48; | n=48; | |
| 26.0 (25.0) | 24.3 (18.0) | ||
| 6 months | n=38; | n=41; | −2.4 (−7.6 to 3.4) |
| 12.7 (14.4) | 15.2 (13.2) | ||
| 12 months | n=37; | n=42; | −1.7 (−8.0 to 4.6) |
| 12.8 (14.8) | 15.8 (15.8) | ||
| PFDI-SF20; UDI-6 domain (0–100, higher=worse pain)* | |||
| Baseline | n=48; | n=49; | |
| 34.8 (22.6) | 37.9 (26.7) | ||
| 6 months | n=38; | n=41; | 0.5 (−8.9 to 7.9) |
| 16.4 (17.5) | 17.2 (18.5) | ||
| 12 months | n=36; | n=42; | 0.7 (−9.1 to 10.4) |
| 20.3 (17.5) | 21.5 (25.3) | ||
| PFDI-SF20; summary score (0–300, higher=worse pain)* | |||
| Baseline | n=48; | n=48; | |
| 104.3 (62.8) | 107.0 (57.4) | ||
| 6 months | n=38; | n=41; | 0.6 (−18.4 to 17.2) |
| 45.4 (43.8) | 45.0 (37.1) | ||
| 12 months | n=36; | n=41; | 4.8 (−16.2 to 25.8) |
| 49.8 (44.1) | 51.1 (47.7) | ||
| PFIQ-7; UIQ-7 domain (0–100, higher=worse condition)* | |||
| Baseline | n=50; | n=50; | |
| 21.0 (25.8) | 21.5 (24.6) | ||
| 6 months | n=38; | n=41; | 1.3 (−6.9 to 9.5) |
| 9.6 (21.7) | 5.9 (11.2) | ||
| 12 months | n=37; | n=42; | 1.4 (−6.0 to 8.8) |
| 8.9 (16.8) | 8.0 (13.9) | ||
| PFIQ-7; CRAIQ-7 domain (0–100, higher=worse condition)* | |||
| Baseline | n=50; | n=50; | |
| 12.0 (21.0) | 8.7 (13.5) | ||
| 6 months | n=38; | n=41; | 1.6 (−2.5 to 5.8) |
| 4.9 (13.1) | 2.4 (6.1) | ||
| 12 months | n=36; | n=42; | 2.2 (−2.8 to 7.1) |
| 4.5 (16.3) | 2.9 (6.1) | ||
| PFIQ-7; POPIQ-7 domain (0–100, higher=worse condition)* | |||
| Baseline | n=50; | n=50; | |
| 17.7 (21.2) | 17.1 (22.1) | ||
| 6 months | n=38; | n=41; | 2.5 (−2.5 to 7.5) |
| 5.0 (13.4) | 2.3 (6.1) | ||
| 12 months | n=36; | n=42; | 0.2 (−2.7 to 3.1) |
| 1.9 (6.8) | 1.7 (5.2) | ||
| PFIQ-7; summary score (0–300, higher=worse pain)* | |||
| Baseline | n=50; | n=50; | |
| 50.8 (54.8) | 47.3 (51.9) | ||
| 6 months | n=38; | n=41; | 6.2 (−8.7 to 21.2) |
| 19.5 (39.8) | 10.7 (19.8) | ||
| 12 months | n=36; | n=42; | 4.5 (−6.8 to 15.8) |
| 14.3 (29.1) | 12.7 (18.3) | ||
| PISQ-12 (0–48, higher=better sexual function)† | |||
| Baseline | n=18; | n=19; | |
| 31.2 (6.5) | 33.1 (7.3) | ||
| 6 months | n=11; | n=14; | −2.4 (−7.0, 2.2) |
| 33.1 (4.1) | 36.1 (5.7) | ||
| 12 months | n=11; | n=10; | 3.4 (0.6 to 6.2) |
| 34.5 (2.7) | 32.8 (5.1) | ||
*<0 indicates less pain/better condition failures with oestrogen.
†>0 indicates better with oestrogen.
‡Differences are adjusted for baseline score and minimisation variables.
CRADI-8, Colorectal-Anal Distress Inventory; CRAIQ-7, Colorectal-Anal Impact; PFDI-SF20, Pelvic Floor Distress Inventory Short Form 20; PFIQ-7, Pelvic Floor Impact Questionnaire; PISQ-12, Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire; POPDI-6, Pelvic Organ Prolapse Distress Inventory; UDI-6, Urinary Distress Inventory.